PhaseRx, Inc. (NASDAQ:PZRX) Files An 8-K Other Events
Item 8.01.
| Other Events. |
On November 28, 2016, the Company issued a press release
announcing Orphan Drug Designation for PRX-OTC for the Treatment
of Ornithine Transcarbamylase Deficiency. A copy of this press
release is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press release, dated November 28,2016 |
About PhaseRx, Inc. (NASDAQ:PZRX)
PhaseRx, Inc is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. The Company’s initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body’s inability to remove ammonia from the blood. The Company’s i-ERT approach is enabled by its Hybrid mRNA Technology platform and is applicable to a number of inherited liver diseases. The Company is headquartered in Seattle. PhaseRx, Inc. (NASDAQ:PZRX) Recent Trading Information
PhaseRx, Inc. (NASDAQ:PZRX) closed its last trading session 00.00 at 1.13 with 241,186 shares trading hands.
